MCID: BCK003
MIFTS: 46

Background Diabetic Retinopathy

Categories: Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Background Diabetic Retinopathy

MalaCards integrated aliases for Background Diabetic Retinopathy:

Name: Background Diabetic Retinopathy 12 15
Non Proliferative Diabetic Retinopathy 12
Non-Proliferative Diabetic Retinopathy 12
Nonproliferative Diabetic Retinopathy 70

Classifications:



External Ids:

Disease Ontology 12 DOID:13208
ICD9CM 34 362.03
NCIt 50 C35668
SNOMED-CT 67 390834004
UMLS 70 C0004606

Summaries for Background Diabetic Retinopathy

MalaCards based summary : Background Diabetic Retinopathy, also known as non proliferative diabetic retinopathy, is related to severe nonproliferative diabetic retinopathy and diabetic macular edema. An important gene associated with Background Diabetic Retinopathy is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are TGF-Beta Pathway and PAK Pathway. The drugs Levoleucovorin and Hydroxocobalamin have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and bone, and related phenotypes are homeostasis/metabolism and cardiovascular system

Related Diseases for Background Diabetic Retinopathy

Diseases related to Background Diabetic Retinopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 744)
# Related Disease Score Top Affiliating Genes
1 severe nonproliferative diabetic retinopathy 31.9 VEGFA PGF INS ICAM1 GADD45G ALB
2 diabetic macular edema 30.9 VEGFA IL6 ICAM1 AKR1B1
3 retinal microaneurysm 30.5 VEGFA INS GADD45G AKR1B1
4 proteinuria, chronic benign 30.5 VEGFA INS ALB ACE
5 hemangioma 30.2 VEGFA KDR IL6 ANGPT2
6 hypertensive retinopathy 30.2 VEGFA CRP ALB ACE
7 lipid metabolism disorder 30.0 INS IL6 CRP ACE
8 microvascular complications of diabetes 1 30.0 VEGFB VEGFA TNF PGF KDR INS
9 hyperglycemia 29.6 SORD INS IL6 ALB AKR1B1 AGER
10 microvascular complications of diabetes 5 29.3 VEGFA SORD PGF KDR INS ICAM1
11 cataract 29.1 VEGFA TNF SORD INS IL6 ICAM1
12 optic nerve disease 29.0 VEGFA TNF IL6 IL1B EDN1 CRP
13 type 1 diabetes mellitus 28.8 VEGFA TNF INS IL6 IL1B ICAM1
14 macular retinal edema 28.8 VEGFB VEGFA TNF PGF KDR INS
15 vascular disease 28.4 VEGFA TNF INS IL6 ICAM1 EDN1
16 type 2 diabetes mellitus 27.9 VEGFA TNF KDR INS IL6 IL1B
17 retinal vascular disease 27.7 VEGFB VEGFA TNF PGF KDR INS
18 diabetes mellitus 27.2 VEGFA TNF SORD PGF KDR INS
19 microvascular complications of diabetes 2 11.0
20 yemenite deaf-blind hypopigmentation syndrome 10.5
21 heterophyiasis 10.4 ICAM1 ALB
22 retroperitoneal hemangiopericytoma 10.4 VEGFA INS
23 rubeosis iridis 10.4 VEGFA INS
24 orthostatic proteinuria 10.4 ALB ACE
25 kidney hypertrophy 10.3 INS ALB ACE
26 hypertensive nephropathy 10.3 VEGFA ALB ACE
27 osteosclerotic myeloma 10.3 VEGFA IL6
28 epithelioid hemangioendothelioma 10.3 VEGFA PGF KDR
29 diabetic autonomic neuropathy 10.3 INS AKR1B1 ACE
30 severe pre-eclampsia 10.3 VEGFA PGF ALB
31 peripartum cardiomyopathy 10.3 VEGFA PGF ACE
32 chronic duodenal ileus 10.3 CRP ALB
33 malignant otitis externa 10.3 INS CRP
34 uvulitis 10.3 INS CRP
35 blood protein disease 10.3 VEGFA IL6 ALB
36 type 1 diabetes mellitus 23 10.3 TNF INS
37 fuchs' heterochromic uveitis 10.3 IL6 ACE
38 diabetic cataract 10.3 VEGFA SORD AKR1B1
39 acute dacryoadenitis 10.3 CRP ACE
40 glomerular disease 10.3 ALB ACE
41 capillary hemangioma 10.3 VEGFA KDR ANGPT2
42 idiopathic nephrotic syndrome 10.3 IL6 ALB ACE
43 external pathological resorption 10.2 TNF IL6
44 mediastinum teratoma 10.2 CRP ACE
45 scorpion envenomation 10.2 TNF IL6
46 toxicodendron dermatitis 10.2 TNF ICAM1
47 cardiac tuberculosis 10.2 CRP ACE
48 idiopathic edema 10.2 INS EDN1 ACE
49 peptic ulcer perforation 10.2 CRP ALB
50 acute mountain sickness 10.2 VEGFA EDN1 ACE

Graphical network of the top 20 diseases related to Background Diabetic Retinopathy:



Diseases related to Background Diabetic Retinopathy

Symptoms & Phenotypes for Background Diabetic Retinopathy

MGI Mouse Phenotypes related to Background Diabetic Retinopathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 ACE AGER AKR1B1 ALB ANGPT2 CRP
2 cardiovascular system MP:0005385 10.35 ACE AGER ALB ANGPT2 CRP EDN1
3 immune system MP:0005387 10.21 ACE AGER ALB ANGPT2 CRP GADD45G
4 endocrine/exocrine gland MP:0005379 10.13 ACE ALB ANGPT2 EDN1 GADD45G ICAM1
5 digestive/alimentary MP:0005381 10.06 ALB ANGPT2 EDN1 ICAM1 IL6 INS
6 integument MP:0010771 10.02 AGER ANGPT2 ICAM1 IL1B IL6 INS
7 muscle MP:0005369 9.91 AGER ALB EDN1 ICAM1 IL6 INS
8 neoplasm MP:0002006 9.76 ACE ALB ICAM1 IL1B IL6 PGF
9 renal/urinary system MP:0005367 9.61 ACE AGER AKR1B1 ALB EDN1 GADD45G
10 vision/eye MP:0005391 9.4 ACE AKR1B1 ANGPT2 ICAM1 IL6 INS

Drugs & Therapeutics for Background Diabetic Retinopathy

Drugs for Background Diabetic Retinopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
2
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
3
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
4
Ranibizumab Approved Phase 4 347396-82-1 459903
5 Grape Approved Phase 4
6
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
7
tannic acid Approved Phase 4 1401-55-4
8
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
9
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
10
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
11
Cobalamin Experimental Phase 4 13408-78-1 6857388
12 Vitamin B12 Phase 4
13 Vitamin B 6 Phase 4
14 Vitamin B 12 Phase 4
15 Hematinics Phase 4
16 Angiogenesis Inhibitors Phase 4
17 Anesthetics Phase 4
18 Hypoglycemic Agents Phase 4
19 insulin Phase 4
20 Insulin, Globin Zinc Phase 4
21 Hormones Phase 4
22 Coagulants Phase 4
23 Calcium Dobesilate Phase 4
24 Hemostatics Phase 4
25 Calcium, Dietary Phase 4
26
Pyridoxal Experimental, Nutraceutical Phase 4 66-72-8 1050
27
Calcium Nutraceutical Phase 4 7440-70-2 271
28
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
29
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
30
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
31
Nepafenac Approved, Investigational Phase 3 78281-72-8 151075
32
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
33
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
34
Fenofibrate Approved Phase 3 49562-28-9 3339
35
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
36
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
37
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
38 Chinese Salvia Phase 3
39 Antirheumatic Agents Phase 3
40 Methylprednisolone Acetate Phase 3
41 Antiemetics Phase 3
42 Neuroprotective Agents Phase 3
43 Anti-Inflammatory Agents Phase 3
44 Hormone Antagonists Phase 3
45 glucocorticoids Phase 3
46 Analgesics Phase 3
47 Anti-Inflammatory Agents, Non-Steroidal Phase 3
48 Analgesics, Non-Narcotic Phase 3
49 Hypolipidemic Agents Phase 3
50 Lipid Regulating Agents Phase 3

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
2 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
3 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
4 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
5 Prospective, Single-center, Six-month Study of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-perfused Retinal Area Completed NCT02834663 Phase 4 Lucentis
6 A Multicenter, Randomized, Double-blind Non-inferiority Trial to Evaluate the Efficacy and Safety of Entelon® as Compared to Doxium Tab. And Placebo for the Treatment of Nonproliferative Diabetic Retinopathy Completed NCT03962296 Phase 4 Vitis vinifera extract;Calcium Dobesilate;Placebo
7 Effect of Continuous Positive Airway Pressure on the Progression of Vascular Retinal Disease in Patients With Sleep Apnea and Non-proliferative Diabetic Retinopathy. A Randomized Clinical Trial Active, not recruiting NCT02874313 Phase 4 Pharmacological treatment
8 Efficacy of Calcium Dobesilate in Treating Chinese Patients With Mild to Moderate Non-proliferative Diabetic Retinopathy (CALM-DR): a Single-blind, Multicenter, Cluster-randomized, Controlled Trial Not yet recruiting NCT04283162 Phase 4 Calcium Dobesilate
9 The Evaluation of Retinal PhotoReceptors And Vasculature in Moderate and Severe Non-proliferative Diabetic Retinopathy Patients After Intravitreal Aflibercept on Using Adaptive Optics Imaging Study (PRAVA) Study Not yet recruiting NCT04702048 Phase 4 Aflibercept Injection;Sham injection
10 A Randomized, Double Blind, Multi-Center Study of Compound Danshen Dripping Pills in Patients With Diabetic Retinopathy (Syndrome Of Qi-Stagnation and Blood Stasis) Unknown status NCT02388984 Phase 3 Compound danshen dripping pills;Placebo
11 Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery Completed NCT01853072 Phase 3 Nepafenac Ophthalmic Suspension, 0.3%;Prednisolone acetate
12 Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery Completed NCT01872611 Phase 3 Nepafenac Ophthalmic Suspension, 0.3%;Prednisolone acetate
13 A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy Completed NCT02718326 Phase 3 Intravitreal aflibercept injection [IAI];Sham
14 A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening Recruiting NCT04661358 Phase 3 Fenofibrate 160mg
15 Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk Active, not recruiting NCT02634333 Phase 3 Prompt aflibercept;Deferred aflibercept
16 Efficacy and Safety of Intravitreal Bevacizumab for the Improvement of Severe Non-proliferative Diabetic Retinopathy Without DME: a Randomized Clinical Trial Not yet recruiting NCT04511715 Phase 2, Phase 3 Intravitreal Bevacizumab IVB
17 An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR) Terminated NCT00248157 Phase 3 Octreotide acetate in microspheres
18 An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR) Terminated NCT00248131 Phase 3 Octreotide acetate in microspheres
19 Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy Completed NCT03197870 Phase 2 AKB-9778;Placebo
20 Protocol PVD-202: A Phase 2, Randomized, Double-Masked, Placebo-Controlled Multicenter Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD in Non-Proliferative Diabetic Retinopathy Completed NCT02435862 Phase 2 1.0mg Luminate®;2.0mg Luminate®;3.0mg Luminate®
21 Efficacy of Ubiquinone and Combined Antioxidant Therapy on Progression, Oxidative Stress Markers and Mitochondrial Dysfunction in Non-proliferative Diabetic Retinopathy: A Phase 2a Randomized Double-blind Placebo-controlled Study Completed NCT02062034 Phase 2 Ubiquinone;Combined antioxidant therapy;Placebo
22 Proof-of-Concept 2 (POC2): Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy Progression in Patients With Mild to Moderate Non-Proliferative Diabetic Retinopathy Completed NCT00917553 Phase 2 doxycycline monohydrate;Placebo
23 An Open-label Assessment of Intravitreous Injections of Vitrase (Hyaluronidase for Injection) for Inducing Posterior Vitreous Detachment in Subjects With Moderate to Severe Non-proliferative Diabetic Retinopathy Completed NCT00198471 Phase 2 Vitrase
24 A Randomized, Double-masked, Placebo-controlled Exploratory Study to Evaluate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Orally Administered BI 1467335 for 12 Weeks With a 12 Week Follow up Period in Patients With Non-proliferative Diabetic Retinopathy Without Center-involved Diabetic Macular Edema (ROBIN Study) Completed NCT03238963 Phase 2 BI 1467335;Placebo
25 Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects With Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy and Mild Proliferative Diabetic Retinopathy Recruiting NCT04692688 Phase 2 APX3330;Placebo
26 A Phase 2 Randomized, Placebo-controlled, Double-masked Proof-of-concept and Dose-finding Study to Investigate the Efficacy and Safety of Runcaciguat (BAY 1101042) in Patients With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy Recruiting NCT04722991 Phase 2 Runcaciguat (BAY1101042)
27 A Randomized, Double-masked, Placebo-controlled Phase 1b/2a Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ in Patients With Non-proliferative Diabetic Retinopathy Without Center-involved Diabetic Macular Edema. Recruiting NCT04552600 Phase 1, Phase 2 Nuvastatic
28 A Randomized, Open-label, Multicenter Study of the Efficacy and Safety of RC28-E Injection in Subjects With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy Not yet recruiting NCT04782128 Phase 2
29 A Phase 2, Randomised, Double Masked, Sham Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total Posterior Vitreous Detachment (PVD) in Subjects With Non-proliferative Diabetic Retinopathy (NPDR) Terminated NCT02681809 Phase 2 ocriplasmin 0.0625mg;ocriplasmin 0.125mg;Sham injection
30 Randomized, Parallel Controlled, Clinical-trial on 532nm Laser Partially Subthreshold Panretinal Photocoagulation With PASCAL Endpoint Management Function for Severe Non-proliferative Diabetic Retinopathy(NPDR) Unknown status NCT01759121
31 Diabetic Macular Edema and Diabetic Retinopathy Identification by Screening (Telemed) With Verified Automated Retinal Photography Unknown status NCT01790945
32 Biomarkers of Diabetic Retinopathy Progression. Completed NCT01607190
33 Identifying Progression of Retinal Disease in Eyes With Non Proliferative Diabetic Retinopathy in Diabetes Type 2 Using Non-invasive Procedures Completed NCT01145599
34 Phenotypes of Nonproliferative Diabetic Retinopathy in Diabetes Type 2 Patients Identified by Optical Coherence Tomography, Colour Fundus Photography, Fluorescein Leakage and Multifocal Electrophysiology (DIAMARKER Project: Genetic Susceptibility for Multi-systemic Complications in Diabetes Type-2: New Biomarkers for Diagnostic and Therapeutic Monitoring). Completed NCT01440660
35 Validation of a Predictive Model to Estimate the Risk of Conversion to Clinically Significant Macular Edema and/or Vision Loss in Mild Nonproliferative Diabetic Retinopathy in Diabetes Type 2 Completed NCT00763802
36 Panretinal Photocoagulation (PRP) vs PRP Combined With Intravitreous Conbercept (IVC) for Severe Nonproliferative Diabetic Retinopathy (nPDR): A Randomized Clinical Trial Recruiting NCT03863535 Conbercept
37 Micro-invasive Pars-plana Vitrectomy vs Panretinal Photocoagulation for Severe Non-Proliferative Diabetic Retinopathy A Randomized Clinical Trial Recruiting NCT04103671
38 Characterization of Retinal Vascular Disease in Eyes With Mild to Moderate NPDR in Diabetes Type 2, Using Novel Non-invasive Imaging Methods, in a Longitudinal, Prospective and Interventional Clinical Study With 2 Years of Duration (CORDIS) Active, not recruiting NCT03696810
39 The Effect of Combination of Vitamin A, Vitamin E, Sodium Hyaluronate 0.15% Eye Drop Compared With Sodium Hyaluronate 0.1% Eye Drop to Tear Film Stability and Conjunctival Goblet Cells Density in Patient With Non-Proliferative Diabetic Retinopathy (NPDR), and Proliferative Diabetic Retinopathy (PDR) Not yet recruiting NCT04000789 Sodium Hyaluronate, Vitamin A, Vitamin E
40 Characterization of Retinal Disease Progression in Eyes With Non Proliferative Diabetic Retinopathy (NPDR) in Diabetes Type 2 Using Non-invasive Procedures (CHART) Not yet recruiting NCT04636307
41 Retinal Neurodegeneration In Patients With Type 2 Diabetes Mellitus Without Diabetic Retinopathy or With Mild Non Proliferative Diabetic Retinopathy Detected by Optical Coherence Tomography Not yet recruiting NCT04808804
42 Pilot Study: The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy Terminated NCT01880372
43 Pascal Pan Retinal Photo-Stimulation in Pre-Proliferative Diabetic Retinopathy: a Safety and Efficacy Study Withdrawn NCT02309502

Search NIH Clinical Center for Background Diabetic Retinopathy

Genetic Tests for Background Diabetic Retinopathy

Anatomical Context for Background Diabetic Retinopathy

MalaCards organs/tissues related to Background Diabetic Retinopathy:

40
Heart, Kidney, Bone, Endothelial, Eye, Liver, Brain

Publications for Background Diabetic Retinopathy

Articles related to Background Diabetic Retinopathy:

(show top 50) (show all 699)
# Title Authors PMID Year
1
Morphological features of focal choroidal excavation and its association with macular pathology in Asian Indian eyes. 61
33727453 2021
2
The Relationship between Choroidal Thickness and Intracellular Oxidised-reduced Glutathione and Extracellular Thiol-disulfide Homeostasis at Different Stages of Diabetic Retinopathy. 61
33103488 2021
3
Macular pigment optical density after panretinal photocoagulation. 61
32869395 2021
4
Survey on recent developments in automatic detection of diabetic retinopathy. 61
33526268 2021
5
Epidemiology of moderately severe and severe non-proliferative diabetic retinopathy in South West England. 61
33692539 2021
6
Evaluation of morphological characteristics of diabetic macular edema in patients with non-proliferative versus proliferative diabetic retinopathy: a spectral-domain optical coherence tomography study. 61
33772414 2021
7
Prevalence of Diabetic Retinopathy in Oman: A Two Decade National Study. 61
33768969 2021
8
Association of serum and aqueous humor myonectin concentrations with diabetic retinopathy. 61
33785845 2021
9
Profiles of intra-day glucose in Type 2 Diabetes and their association with complications: an analysis of continuous glucose monitoring data. 61
33720761 2021
10
Handheld fundus camera performance, image quality and outcomes of diabetic retinopathy grading in a pilot screening study. 61
33724706 2021
11
Microinvasive pars plana vitrectomy versus panretinal photocoagulation in the treatment of severe non-proliferative diabetic retinopathy (the VIP study): study protocol for a randomised controlled trial. 61
33619191 2021
12
Non-proliferative diabetic retinopathy. 61
33541706 2021
13
Analyzing fundus images to detect diabetic retinopathy (DR) using deep learning system in the Yangtze River delta region of China. 61
33708853 2021
14
Associations between attainment of incentivized primary care indicators and incident sight-threatening diabetic retinopathy in England: A population-based historical cohort study. 61
33565708 2021
15
Diabetic Retinopathy Screening Using Artificial Intelligence and Handheld Smartphone-Based Retinal Camera. 61
33435711 2021
16
Association between risk factors and retinal nerve fiber layer loss in early stages of diabetic retinopathy. 61
33614455 2021
17
Widefield optical coherence tomography angiography for early detection and objective evaluation of proliferative diabetic retinopathy. 61
32193221 2021
18
Non-invasive structural and metabolic retinal markers of disease activity in non-proliferative diabetic retinopathy. 61
33416216 2021
19
Intravitreal aflibercept partially reverses severe non-proliferative diabetic retinopathy in treatment-naïve patients. 61
33499698 2021
20
Diabetic retinopathy in the Eastern Morocco: Different stage frequencies and associated risk factors. 61
33424367 2021
21
Dilated retinal large vessels and capillaries associated with diabetic macular edema and photoreceptor loss respectively. 61
33417093 2021
22
Association of Bone Metabolism Indices and Bone Mineral Density with Diabetic Retinopathy in Elderly Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Inpatient Study in China. 61
33506053 2021
23
Transient Cortical Blindness After Coronary Angiography, Bypass Graft Angiography, and Coronary Angioplasty. 61
33425567 2021
24
The Association Between HbA1c and Other Biomarkers With the Prevalence and Severity of Diabetic Retinopathy. 61
33564524 2021
25
Efficacy and Safety of TangWang Prescription for Type 2 Non-Proliferative Diabetic Retinopathy: A Study Protocol for a Randomized Controlled Trial. 61
33790783 2021
26
Plasma cytokines for predicting diabetic retinopathy among type 2 diabetic patients via machine learning algorithms. 61
33323553 2020
27
Anemia and Diabetic Kidney Disease Had Joint Effect on Diabetic Retinopathy Among Patients With Type 2 Diabetes. 61
33351059 2020
28
Detection of neovascularisation in the vitreoretinal interface slab using widefield swept-source optical coherence tomography angiography in diabetic retinopathy. 61
33355148 2020
29
TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy. 61
33334029 2020
30
Swept-source OCTA quantification of capillary closure predicts ETDRS severity staging of NPDR. 61
33355147 2020
31
Vascular density of optic nerve head in diabetic retinopathy using optical coherence tomography angiography. 61
33292768 2020
32
RNA-Seq reveals placental growth factor regulates the human retinal endothelial cell barrier integrity by transforming growth factor (TGF-β) signaling. 61
32813141 2020
33
Expression of Neovascular Associated Factors PEDF and αB-crystallin in Human Lens Epithelial Cells. 61
32208037 2020
34
Follow-Up Adherence in Patients with Non-Proliferative Diabetic Retinopathy Presenting to an Ophthalmic Emergency Department. 61
33252579 2020
35
Serum progesterone and retinopathy in male patients with type 2 diabetes: A cross-sectional study. 61
33202100 2020
36
Normal parathyroid hormone and non-proliferative diabetic retinopathy in patients with type 2 diabetes. 61
33135333 2020
37
Associations of serum uric acid and urinary albumin with the severity of diabetic retinopathy in individuals with type 2 diabetes. 61
33256661 2020
38
The changing features of serum adropin, copeptin, neprilysin and chitotriosidase which are associated with vascular endothelial function in type 2 diabetic retinopathy patients. 61
32768333 2020
39
Continuous wavelet transform analysis of ERG in patients with diabetic retinopathy. 61
33226538 2020
40
Retinopathy secondary to multiple myeloma treated with bevacizumab. 61
32636041 2020
41
MicroRNA Expression in the Aqueous Humor of Patients with Diabetic Macular Edema. 61
33023063 2020
42
Eye hemodynamic data and biochemical parameters of the lacrimal fluid of patients with non-proliferative diabetic retinopathy. 61
32923547 2020
43
Subthreshold Pan-retinal Photocoagulation Using Endpoint Management Algorithm for Severe Non-proliferative Diabetic Retinopathy: A Paired Controlled Pilot Prospective Study. 61
33053561 2020
44
Quantification of diabetic macular ischemia using novel three-dimensional optical coherence tomography angiography metrics. 61
32526048 2020
45
[Observation and quantification of diabetic keratopathy in type 2 diabetes patients using in vivo laser confocal microscopy]. 61
33059418 2020
46
Comparison of inflammatory cytokines levels in the aqueous humor with diabetic retinopathy. 61
32556740 2020
47
Z-Ligustilide Ameliorates Diabetic Rat Retinal Dysfunction Through Anti-Apoptosis and an Antioxidation Pathway. 61
33011733 2020
48
Vascular changes precede tomographic changes in diabetic eyes without retinopathy and improve artificial intelligence diagnostics. 61
32392370 2020
49
DIABETIC MACULAR EDEMA AND CATARACT SURGERY: PHACOEMULSIFICATION COMBINED WITH DEXAMETHASONE INTRAVITREAL IMPLANT COMPARED WITH STANDARD PHACOEMULSIFICATION. 61
32897932 2020
50
Quantification of vascular and neuronal changes in the peripapillary retinal area secondary to diabetic retinopathy. 61
32933938 2020

Variations for Background Diabetic Retinopathy

Expression for Background Diabetic Retinopathy

Search GEO for disease gene expression data for Background Diabetic Retinopathy.

Pathways for Background Diabetic Retinopathy

Pathways related to Background Diabetic Retinopathy according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.53 VEGFB VEGFA TNF PGF KDR INS
2
Show member pathways
13.31 VEGFB TNF PGF KDR IL6 IL1B
3
Show member pathways
13.06 VEGFB PGF KDR INS IL6 ACE
4
Show member pathways
12.95 VEGFA TNF IL6 IL1B ICAM1 ANGPT2
5
Show member pathways
12.91 VEGFB VEGFA TNF PGF KDR INS
6 12.86 VEGFB VEGFA PGF IL6 GADD45G EDN1
7
Show member pathways
12.86 VEGFA TNF INS IL6 IL1B ICAM1
8
Show member pathways
12.75 VEGFB VEGFA PGF KDR INS ANGPT2
9
Show member pathways
12.71 VEGFB TNF PGF KDR IL6 IL1B
10 12.28 VEGFB VEGFA TNF PGF KDR INS
11
Show member pathways
12.27 VEGFB TNF PGF KDR IL6 IL1B
12
Show member pathways
12.26 TNF IL6 EDN1 ACE
13
Show member pathways
12.23 TNF IL6 IL1B EDN1
14 12.19 VEGFA TNF IL6 IL1B
15 12.05 VEGFA KDR INS IL6 ALB
16 12.03 TNF IL6 IL1B ICAM1
17
Show member pathways
12.03 TNF INS IL6 IL1B ICAM1 CRP
18 11.97 VEGFA TNF IL6 IL1B ICAM1
19 11.95 TNF IL1B ICAM1 GADD45G
20 11.94 TNF IL6 IL1B ICAM1 EDN1
21 11.94 VEGFA TNF KDR IL1B ICAM1 EDN1
22
Show member pathways
11.88 VEGFB VEGFA PGF KDR
23 11.87 VEGFA INS IL6 EDN1 ANGPT2
24
Show member pathways
11.77 TNF IL6 IL1B
25 11.77 TNF IL6 IL1B
26 11.77 VEGFA TNF IL6 IL1B ICAM1
27 11.75 TNF IL6 IL1B
28 11.7 TNF IL6 ICAM1
29 11.68 TNF IL6 IL1B EDN1
30 11.63 TNF IL6 IL1B
31 11.6 VEGFB VEGFA EDN1
32
Show member pathways
11.57 VEGFA TNF IL6 IL1B ICAM1
33 11.56 TNF IL6 IL1B ICAM1
34 11.54 VEGFA INS IL6
35 11.54 TNF IL6 IL1B ICAM1
36 11.52 TNF IL6 ICAM1 AGER
37 11.51 TNF IL6 IL1B
38 11.48 VEGFB VEGFA KDR
39 11.41 VEGFA EDN1 ANGPT2
40 11.4 VEGFA KDR INS
41 11.38 TNF IL6 IL1B
42 11.34 TNF IL6 IL1B
43 11.33 TNF IL6 IL1B ICAM1
44 11.31 TNF IL6 IL1B
45
Show member pathways
11.3 VEGFA EDN1 CRP
46 11.27 TNF IL6 IL1B
47 11.23 VEGFB VEGFA TNF IL6 IL1B ICAM1
48 11.06 TNF IL6 CRP
49 11.01 VEGFB TNF PGF KDR IL6 IL1B
50 10.98 TNF IL1B ICAM1

GO Terms for Background Diabetic Retinopathy

Cellular components related to Background Diabetic Retinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 VEGFB VEGFA TNF PGF KDR INS
2 extracellular space GO:0005615 9.5 VEGFB VEGFA TNF SORD PGF INS
3 platelet alpha granule lumen GO:0031093 9.33 VEGFB VEGFA ALB

Biological processes related to Background Diabetic Retinopathy according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.16 VEGFB VEGFA KDR IL6 ALB AKR1B1
2 positive regulation of gene expression GO:0010628 10.15 VEGFA TNF INS IL6 IL1B CRP
3 inflammatory response GO:0006954 10.12 TNF IL6 IL1B CRP AGER
4 positive regulation of cell proliferation GO:0008284 10.1 VEGFA PGF KDR INS IL6 IL1B
5 cytokine-mediated signaling pathway GO:0019221 10.09 VEGFA TNF IL6 IL1B ICAM1
6 positive regulation of cell migration GO:0030335 10.06 VEGFA KDR INS IL1B EDN1
7 angiogenesis GO:0001525 10.05 VEGFB VEGFA PGF KDR ANGPT2
8 cell-cell signaling GO:0007267 10.04 PGF INS IL1B EDN1
9 positive regulation of protein kinase B signaling GO:0051897 10.02 VEGFB VEGFA TNF INS
10 cellular response to lipopolysaccharide GO:0071222 10.02 TNF IL6 IL1B ICAM1
11 negative regulation of gene expression GO:0010629 10.01 VEGFB VEGFA TNF KDR EDN1 ACE
12 positive regulation of MAPK cascade GO:0043410 9.98 VEGFA KDR INS IL6
13 positive regulation of DNA-binding transcription factor activity GO:0051091 9.97 TNF IL6 IL1B EDN1
14 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.94 VEGFB VEGFA IL6 ICAM1
15 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.93 VEGFA TNF KDR INS
16 positive regulation of interleukin-6 production GO:0032755 9.93 TNF IL6 IL1B AGER
17 positive regulation of JNK cascade GO:0046330 9.92 TNF IL1B GADD45G AGER
18 regulation of insulin secretion GO:0050796 9.91 TNF IL6 IL1B
19 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.91 VEGFA TNF IL6
20 positive regulation of endothelial cell migration GO:0010595 9.91 VEGFA KDR EDN1
21 positive regulation of endothelial cell proliferation GO:0001938 9.91 VEGFB VEGFA PGF KDR
22 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 VEGFB VEGFA TNF KDR ICAM1 AGER
23 glucose metabolic process GO:0006006 9.9 TNF SORD INS
24 positive regulation of MAP kinase activity GO:0043406 9.9 VEGFA TNF EDN1
25 positive regulation of interleukin-8 production GO:0032757 9.9 TNF IL6 IL1B
26 positive regulation of interleukin-1 beta production GO:0032731 9.9 TNF IL6 AGER
27 response to activity GO:0014823 9.89 IL6 EDN1 ANGPT2
28 positive chemotaxis GO:0050918 9.88 VEGFB VEGFA PGF
29 protein kinase B signaling GO:0043491 9.88 TNF KDR IL1B
30 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 TNF IL1B EDN1 AGER
31 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.88 VEGFB VEGFA PGF KDR
32 positive regulation of chemokine production GO:0032722 9.87 TNF IL6 AGER
33 acute-phase response GO:0006953 9.87 INS IL6 CRP
34 positive regulation of smooth muscle cell proliferation GO:0048661 9.87 TNF IL6 EDN1 AKR1B1
35 positive regulation of JAK-STAT cascade GO:0046427 9.86 TNF IL6 AKR1B1
36 positive regulation of JUN kinase activity GO:0043507 9.86 TNF EDN1 AGER
37 sprouting angiogenesis GO:0002040 9.85 VEGFB VEGFA PGF
38 branching involved in blood vessel morphogenesis GO:0001569 9.85 VEGFA KDR EDN1
39 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 TNF INS IL6 IL1B ICAM1 AGER
40 positive regulation of mitotic nuclear division GO:0045840 9.84 INS IL1B EDN1
41 positive regulation of cell division GO:0051781 9.83 VEGFB VEGFA PGF IL1B
42 negative regulation of neurogenesis GO:0050768 9.82 TNF IL6 IL1B
43 positive regulation of nitric oxide biosynthetic process GO:0045429 9.8 TNF IL1B ICAM1 EDN1
44 positive regulation of angiogenesis GO:0045766 9.8 VEGFB VEGFA PGF KDR IL1B ANGPT2
45 positive regulation of glial cell proliferation GO:0060252 9.79 TNF IL6 IL1B
46 negative regulation of lipid catabolic process GO:0050995 9.79 TNF INS IL1B
47 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.77 TNF IL1B AGER
48 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.77 TNF IL6 ICAM1
49 regulation of establishment of endothelial barrier GO:1903140 9.74 TNF IL1B
50 neutrophil mediated immunity GO:0002446 9.74 IL6 ACE

Molecular functions related to Background Diabetic Retinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.81 VEGFB VEGFA TNF SORD KDR INS
2 growth factor activity GO:0008083 9.67 VEGFB VEGFA PGF IL6
3 chemoattractant activity GO:0042056 9.5 VEGFB VEGFA PGF
4 cytokine activity GO:0005125 9.35 VEGFA TNF IL6 IL1B EDN1
5 vascular endothelial growth factor receptor 1 binding GO:0043183 9.26 VEGFB VEGFA
6 vascular endothelial growth factor receptor binding GO:0005172 8.8 VEGFB VEGFA PGF

Sources for Background Diabetic Retinopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....